Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats postoperative nausea and vomiting. Sold as Tigan. Every FDA application for this active ingredient: 2 branded and 12 generic.
As of Nov 16, 2026, FDA lists 14 applications for Trimethobenzamide Hydrochloride (sold as Tigan), first approved Jul 12, 1974, with 1 new use approved and 0 published complete response letters.
First approved: Jul 12, 1974
Applications: 14
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $465K
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Tigan
Part D
$304K
+55%
197
Trimethobenzamide HCl
Part D
$150K
+61%
213
Tigan
Part B
$11K
-62%
193
Clinical Trials
1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA